Authors:
, , , , , , , , , , , , , , , , , and
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Centers for Disease Control and Prevention, 2009. CDC Health Information for International Travel 2010. Atlanta, GA: Elsevier.
-
2.
Griffith KS, Lewis LS, Mali S, Parise ME, 2007. Treatment of malaria in the United States: a systematic review. JAMA 297: 2264–2277.
-
3.
2008. Tetracyclines. McEvoy G, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc.
-
4.
Rieckmann KH, McNamara JV, Willerson D, Kass L, Frischer J, Carson PE, 1971. Effects of tetracycline against chloroquineresistant and cloroquine-sensitive Plasmodium falcuparum. Am J Trop Med Hyg 20: 811–815.
-
5.
Clyde DF, DuPont HL, Hornick RB, 1971. Antimalarial effects of tetracyclines in man. J Trop Med Hyg 74: 238–242.
-
6.
Colwell EJ, Hickman RL, Intraprasert R, Tirabutana C, 1972. Minocycline and tetracycline treatment of acute falciparum malaria in Thailand. Am J Trop Med Hyg 21: 144–149.
-
7.
Colwell EJ, Hickman RL, Kosakal S, 1972. Tetracycline treatment of chloroquine-resistant falciparum malaria in Thailand. JAMA 220: 684–686.
-
8.
Willerson RK Jr, Carson PE, Frischer H, 1972. Effects of minocycline against chloroquine-resistant falciparum malaria. Am J Trop Med Hyg 21: 857–862.
-
9.
Lacy CF, Armstrong LL, Goldmann MP, Leonard LL, 2006. Lexi Comp's Drug Information Handbook. Hudson, OH: Lexi Comp.
-
10.
Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, Tang DB, Dunne MW, Shanks GD, 1998. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 26: 146–150.
-
11.
Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL, 1995. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 171: 1569–1575.
-
12.
Baudon D, Martet G, Pascal B, Bernard J, Keundjian A, Laroche R, 1999. Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil; a study conducted in 1996 in the French Army. Trans R Soc Trop Med Hyg 93: 302–303.
-
13.
Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ, Handschin J, Tang D, Sandjaja B, Tjitra E, Hadiarso L, Watt G, Wignall FS, 1997. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 126: 963–972.
-
14.
Pang L, Limsomwong N, Singharaj P, 1988. Prophylactic treatment of vivax and falciparum malaria with low-dose doxycycline. J Infect Dis 158: 1124–1127.
-
15.
Pang LW, Limsomwong N, Boudreau EF, Singharaj P, 1987. Doxycycline prophylaxis for falciparum malaria. Lancet 1: 1161–1164.
-
16.
Rieckmann KH, Yeo AE, Davis DR, Hutton DC, Wheatley PF, Simpson R, 1993. Recent military experience with malaria chemoprophylaxis. Med J Aust 158: 446–449
-
17.
Watanasook C, Singharaj P, Suriyamongkol V, Karwacki JJ, Shanks D, Phintuyothin P, Pilungkasa S, Wasuwat P, 1989. Malaria prophylaxis with doxycycline in soldiers deployed to the Thai-Kampuchean border. Southeast Asian J Trop Med Public Health 20: 61–64.
-
18.
Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J, 1999. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 28: 74–81.
-
19.
Sanchez JL, DeFraites RF, Sharp TW, Hanson RK, 1993. Mefloquine or doxycycline prophylaxis in US troops in Somalia. Lancet 341: 1021–1022.
-
20.
Shamiss A, Atar E, Zohar L, Cain Y, 1996. Mefloquine versus doxycycline for malaria prophylaxis in intermittent exposure of Israeli Air Force aircrew in Rwanda. Aviat Space Environ Med 67: 872–873.
-
21.
Shanks GD, Roessler P, Edstein MD, Rieckmann KH, 1995. Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia. Mil Med 160: 443–445.
-
22.
Shanks GD, Barnett A, Edstein MD, Rieckmann KH, 1995. Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. Med J Aust 162: 306–307, 309–310.
-
23.
Shmuklarsky MJ, Boudreau EF, Pang LW, Smith JI, Schneider I, Fleckenstein L, Abdelrahim MM, Canfield CJ, Schuster B, 1994. Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. Ann Intern Med 120: 294–299.
-
24.
Willerson D, Rieckmann KH, Carson PE, Frischer H, 1972. Effects of minocycline against chloroquine-resistant falciparum malaria. Am J Trop Med Hyg 21: 857–862.
-
25.
Clyde DF, 1974. Treatment of drug-resistant malaria in man. Bull World Health Organ 50: 243–249.
-
26.
Taylor WR, Widjaja H, Richie TL, Basri H, Ohrt C, Tjitra Taufik E, Jones TR, Kain KC, Hoffman SL, 2001. Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia. Am J Trop Med Hyg 64: 223–228.
-
27.
Ponnampalam JT, 1981. Doxycycline in the treatment of falciparum malaria among aborigine children in West Malaysia. Trans R Soc Trop Med Hyg 75: 372–377.
-
28.
Alecrim MG, Lacerda MV, Mourao MP, Alecrim WD, Padilha A, Cardoso BS, Boulos M, 2006. Successful treatment of Plasmodium falciparum malaria with a six-doxe regimen of artemether-lumefantrine versus quinine-doxycycline in the Western Amazon regioni of Brazil. Am J Trop Med Hyg 74: 20–25.
-
29.
Ejaz A, Haqnawaz Z, Hussain Z, Butt R, Awan ZI, Bux H, 2007. Treatment of uncomplicated Plasmodium falciparum malaria with quinine-doxycycline combination therapy. J Pak Med Assoc 57: 502–505.
-
30.
White NJ, 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41: 1413–1422.
-
31.
Handfield-Jones RP, 1949. Chloroquine, proguanil, mepacrine and quinine in the treatment of malaria caused by Plasmodium falciparum. Ann Trop Med Parasitol 43: 345–348.
-
32.
Watt G, Loesuttivibool L, Shanks GD, Boundreau EF, Brown AE, Pavanand K, Webster HK, Wechgritaya S, 1992. Quinine with tetracycline for the treatment of drug-resistant falciparum malaria in Thailand. Am J Trop Med Hyg 47: 108–111.
-
33.
Reacher M, Campbell CC, Freeman J, Doberstyn EB, Brandling-Bennett AD, 1981. Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine-sulfadoxine (Fansidar). A study of alternate regimens in Eastern Thailand, 1980. Lancet 2: 1066–1069.
-
34.
Looareesuwan S, Vanijanonta S, Viravan C, Wilairatana P, Charoenlarp P, Lasserre R, Canfield C, Kyle DE, Webster HK, 1994. Randomized trial of mefloquine-tetracycline and quinine-tetracycline for acute uncomplicated falciparum malaria. Acta Trop 57: 47–53.
-
35.
Karbwang J, Molunto P, Bunnag D, Harinasuta T, 1991. Plasma quinine levels in patients with falciparum malaria when given alone or in combination with tetracycline with or without primaquine. Southeast Asian J Trop Med Public Health 22: 72–76.
-
36.
2008. Vibramycin. Physicians' Desk Reference. Montvale, NJ: Thomson PDR.
-
37.
Maibach H, 1991. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis 48: 411–417.
-
38.
Leyden JJ, 1985. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. J Am Acad Dermatol 12: 308–312.
-
39.
Meyer FP, Specht H, Quednow B, Walther H, 1989. Influence of milk on the bioavailability of doxycycline–new aspects. Infection 17: 245–246.
-
40.
2002. Product Information: vibramycin brand of doxycycline monohydrate. New York: Pfizer.
-
41.
2003. Tetracyclines (Systemic). Group UDE, ed. USP DI Drug Information for the Health Care Provider. Greenwood Village, CO: Micromedex, Inc.
-
42.
Cunha BA, Comer JB, Jonas M, 1982. The tetracyclines. Med Clin North Am 66: 293–302.
-
43.
Whelton A, Schach von Wittenau M, Twomey TM, Walker WG, Bianchine JR, 1974. Doxycycline pharmacokinetics in the absence of renal function. Kidney Int 5: 365–371.
-
44.
Binh V, Chinh N, Thanh N, Cuong B, Quang N, Dai B, Travers T, Edstein M, 2009. Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. Am J Trop Med Hyg 81: 747–753.
-
45.
Marussig M, Motard A, Renia L, Baccam D, Lebras J, Charmot G, Mazier D, 1993. Activity of doxycycline against preerythrocytic malaria. J Infect Dis 168: 1603–1604.
-
46.
Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ, 2006. Tetracyclines specifically target the apicoplast of the malaria parasite P. falciparum. Antimicrob Agents Chemother 50: 3124–3131.
-
47.
Budimulja AS, Syafruddin Tapchaisri P, Wilairat P, Marzuki S, 1997. The sensitivity of Plasmodium protein synthesis to prokaryotic ribosomal inhibitors. Mol Biochem Parasitol 84: 137–141.
-
48.
Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ, 2006. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 75: 402–415.
-
49.
Pukrittayakamee S, Imwong M, Singhasivanon P, Stepniewska K, Day N, White N, 2008. Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria. Am J Trop Med Hyg 79: 378–384.
-
50.
Wein S, Maynadier M, Tran Van Ba C, Cerdan R, Peyrottes S, Fraisse L, Vial H, 2010. Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J Clin Microbiol 48: 1651–1660.
-
51.
Dahl E, Rosenthal P, 2007. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother 51: 3485–3490.
-
52.
Pradines B, Spiegel A, Rogier C, Tall A, Mosnier J, Fusai T, Trape JF, Parzy D, 2000. Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity of doxycycline against Senegalese isolates. Am J Trop Med Hyg 62: 82–85.
-
53.
Legrand E, Volney B, Meynard JB, Mercereau-Puijalon O, Esterre P, 2008. In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob Agents Chemother 52: 288–298.
-
54.
Briolant S, Baragatti M, Parola P, Simon F, Tall A, Sokhna C, Hovette P, Mamfoumbi M, Koeck J-L, Delmont J, Spiegel A, Castello J, Gardair J, Trape J, Kombila M, Minodier P, Fusai T, Rogier C, Pradines B, 2009. Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline. Antimicrob Agents Chemother 53: 688–695.
-
55.
Briolant S, Wurtz N, Zettor A, Rogier C, Pradines B, 2010. Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers. J Infect Dis 201: 153–159.
-
56.
Shanks GD, Edstein MD, Suriyamongkol V, Timsaad S, Webster HK, 1992. Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. Am J Trop Med Hyg 46: 643–648.
-
57.
Wallace MR, Sharp TW, Smoak B, Iriye C, Rozmajzl P, Thornton SA, Batchelor R, Magill AJ, Lobel HO, Longer CF, Burans JP, 1996. Malaria among United States troops in Somalia. Am J Med 100: 49–55.
-
58.
Pages F, Boutin JP, Meynard JB, Keundijian A, Ryfer S, Giurato L, Baudon D, 2002. Tolerability of doxycycline monohydrate salt vs. chloroquine-proquanil in malaria chemoprophylaxis. Trop Med Int Health 7: 919–924.
-
59.
Durrheim DN, Gammon S, Waner S, Braack LE, 1999. Antimalarial prophylaxis–use and adverse events in visitors to the Kruger National Park. S Afr Med J 89: 170–175.
-
60.
Waner S, Durrhiem D, Braack LE, Gammon S, 1999. Malaria protection measures used by in-flight travelers to South African game parks. J Travel Med 6: 254–257.
-
61.
Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R, 2007. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicenter, randomized, double blind, four arm study. BMJ 327: 1078–1083.
-
62.
Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE, 1990. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg 43: 608–613.
-
63.
Conrad KA, Kiser WR, 1997. Doxycycline vs. mefloquine. Mil Med 162: viii.
-
64.
Korhonen C, Peterson K, Bruder C, Jung P, 2007. Self-reported adverse events associated with antimalarial chemoprophylaxis in Peace Corps volunteers. Am J Prev Med 33: 194–199.
-
65.
Delpre G, Kadish U, Stahl B, 1989. Induction of esophageal injuries by doxycycline and other pills. A frequent but preventable occurrence. Dig Dis Sci 34: 797–800.
-
66.
Jaspersen D, 2000. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf 22: 237–249.
-
67.
Delpre G, Kadish U, 1981. More on esophageal ulcerations due to tetracycline and doxycycline therapy. Gastrointest Endosc 27: 108–109.
-
68.
Berger RS, 1988. A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R. J Clin Pharmacol 28: 367–370.
-
69.
Layton AM, Cunliffe WJ, 1993. Phototoxic eruptions due to doxycycline–a dose-related phenomenon. Clin Exp Dermatol 18: 425–427.
-
70.
Smith EL, al Raddadi A, al Ghamdi F, Kutbi S, 1995. Tetracycline phototoxicity. Br J Dermatol 132: 316–317.
-
71.
Bjellerup M, Ljunggren B, 1994. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema. Br J Dermatol 130: 356–360.
-
72.
Shea CR, Olack GA, Morrison H, Chen N, Hasan T, 1993. Phototoxicity of lumidoxycycline. J Invest Dermatol 101: 329–333.
-
73.
Vassileva SG, Mateev G, Parish LC, 1998. Antimicrobial photosensitive reactions. Arch Intern Med 158: 1993–2000.
-
74.
Gonzalez E, Gonzalez S, 1996. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 35: 871–885, quiz 886–887.
-
75.
Sobel JD, 1985. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 152: 924–935.
-
76.
McCool L, Mai H, Essmann M, Larsen B, 2008. Tetracycline effects on Candida albicans virulence factors. Infect Dis Obstet Gynecol 2008: 493508.
-
77.
Caruso LJ, 1964. Vaginal moniliasis after tetracycline therapy: the effects of amphotericin B. Am J Obstet Gynecol 90: 374–378.
-
78.
Oriel JD, Waterworth PM, 1975. Effects of minocycline and tetracycline on the vaginal yeast flora. J Clin Pathol 28: 403–406.
-
79.
Hall JH, Lupton ES, 1977. Tetracycline therapy for acne: incidence of vaginitis. Cutis 20: 97–98.
-
80.
Friedman DI, 2005. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol 6: 29–37.
-
81.
Walters BN, Gubbay SS, 1981. Tetracycline and benign intracranial hypertension: report of five cases. Br Med J (Clin Res Ed) 282: 19–20.
-
82.
Winn BJ, Liao YJ, Horton JC, 2007. Intracranial pressure returns to normal about a month after stopping tetracycline antibiotics. Arch Ophthalmol 125: 1137–1138.
-
83.
Meynadier J, Alirezai M, 1998. Systemic antibiotics for acne. Dermatology 196: 135–139.
-
84.
Morrow GL, Abbott RL, 1998. Minocycline-induced scleral, dental, and dermal pigmentation. Am J Ophthalmol 67: 450–455.
-
85.
Loo WJ, Kirtschig G, Wojnarowska F, 2001. Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol 26: 376–379.
-
86.
Ozog DM, Gogstetter DS, Scott G, Gaspari AA, 2000. Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid. Arch Dermatol 136: 1136–1138.
-
87.
Patel K, Cheshire D, Vance A, 1998. Oral and systemic effects of prolonged minocycline therapy. Br Dent J 185: 560–562.
-
88.
Wasel NR, Schloss EH, Lin AN, 1998. Minocycline-induced cutaneous pigmentation. J Cutan Med Surg 3: 105–108.
-
89.
Westermann GW, Bohm M, Bonsmann G, Rahn KH, Kisters K, 1999. Chronic intoxication by doxycycline use for more than 12 years. J Intern Med 246: 591–592.
-
90.
Chiappinelli JA, Walton RE, 1992. Tooth discoloration resulting from long-term tetracycline therapy: a case report. Quintessence Int 23: 539–541.
-
91.
Ho NC, Levy H, Francomano CA, Elkayam O, 2000. Minocycline-induced generalized postinflammatory elastolysis. Am J Med 109: 340–341.
-
92.
Dotevall L, Hagberg L, 2000. Adverse effects of minocycline versus doxycycline in the treatment of Lyme neuroborreliosis. Clin Infect Dis 30: 410–411.
-
93.
Golledge CL, Riley TV, 1995. Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis. Lancet 345: 1377–1378.
-
94.
Baxter R, Ray GT, Fireman B, 2008. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 29: 44–50.
-
95.
2007. Vibramycin [package insert]. New York: Pfizer Labs.
-
96.
Delaney TJ, Leppard BJ, MacDonald DM, 1974. Effects of leng-term treatment with tetracycline. Acta Dematovener (Stockholm) 54: 487–489.
-
97.
Tanzman ES, 1988. Long-term tetracycline use in the treatment of acne vulgaris–the role of routine laboratory monitoring. J Am Coll Health 36: 272–278.
-
98.
Sauer GC, 1976. Safety of long-term tetracycline therapy for acne. Arch Dermatol 112: 1603–1605.
-
99.
Abe M, Furukawa S, Takayama S, Michitaka K, Minami H, Yamamoto K, Horiike N, Onji M, 2003. Drug-induced hepatitis with autoimmune features during minocycline therapy. Intern Med 42: 48–52.
-
100.
Goldstein NS, Bayati N, Silverman AL, Gordon SC, 2000. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 114: 591–598.
-
101.
Gough A, Chapman S, Wagstaff K, Emery P, Elias E, 1996. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 312: 169–172.
-
102.
Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM, 1998. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med 152: 1132–1136.
-
103.
Malcolm A, Heap TR, Eckstein RP, Lunzer MR, 1996. Minocycline-induced liver injury. Am J Gastroenterol 91: 1641–1643.
-
104.
Heaton PC, Fenwick SR, Brewer DE, 2007. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther 32: 483–487.
-
105.
Goulden V, Glass D, Cunliffe WJ, 1996. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 134: 693–695.
-
106.
O'dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, Sems KM, Fernandez AM, Palmer WR, Klassen LW, Paulsen GA, Haire CE, Moore GF, 2001. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 44: 2235–2241.
-
107.
Zhang L, Zhang Y, Zhao P, Huang S, 2009. Predicting drug-drug interactions: and FDA perspective. AAPS J 11: 300–306.
-
108.
Deppermann K, Lode H, Joffken G, Tschink G, Kalz C, Koeppe P, 1989. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycyline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 33: 1901–1907.
-
109.
Helms SE, Bredle DL, Zajic J, Jarjoura D, Brodell RT, Krishnarao I, 1997. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 36: 705–710.
-
110.
Dickinson BD, Altman RD, Nielson NH, Sterling ML, 2001. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 98: 853–860.
-
111.
Neely JL, Abate M, Swinker M, D'Angio R, 1991. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstet Gynecol 77: 416–420.
-
112.
Archer JS, Archer DF, 2002. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 46: 917–923.
-
113.
Baciewicz AM, Bal BS, 2001. Bleeding associated with doxycycline and warfarin treatment. Arch Intern Med 161: 1231.
-
114.
Jawetz E, Gunnison JB, 1952. Studies on antibiotic synergism and antagonism: a scheme of combined antibiotic action. Antibiot Chemother 2: 243–248.
-
115.
Kuzucu EY, 1970. Methoxyflurane, tetracycline, and renal failure. JAMA 211: 1162–1164.
-
116.
Cousins MJ, Mazze RI, 1972. Tetracycline, methoxyflurane anaesthesia, and renal dysfunction. Lancet 1: 751–752.
-
117.
Frascino JA, 1972. Tetracycline, methoxyflurane anaesthesia, and renal dysfunction. Lancet 1: 1127.
-
118.
Lindenbaum J, Rund DG, Butler VP, Tse-eng D, Saha JR, 1981. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 305: 789–794.
-
119.
Lindenbaum J, Tse-eng D, Butler VP, Rund DG, 1981. Urinary excretion of reduced metabolites of digoxin. Am J Med 71: 71–74.
-
120.
Neuvonen PJ, Penttila O, Lehtovaara R, Aho K, 1975. Effect of antiepileptic drugs on the elimination of various tetracycline derivatives. Eur J Clin Pharmacol 9: 147–154.
-
121.
2006. Vivotif [package insert]. Switzerland: Berna Biotech Ltd.
-
122.
Conchie JM, Munroe JD, Anderson DO, 1970. The incidence of staining of permanent teeth by the tetracyclines. CMAJ 103: 351–356.
-
123.
Wallman IS, Hilton HB, 1962. Teeth pigmented by tetracycline. Lancet 1: 827–829.
-
124.
Briggs GG, Freeman RK, Yaffe SJ, 2005. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Philadelphia, PA: Lippincott, Williams, & Wilkins.
-
125.
Grossman ER, Walchek A, Freedman H, 1971. Tetracyclines and permanent teeth: the relation between dose and tooth color. Pediatrics 47: 567–570.
-
126.
Brearley LJ, Storey E, 1968. Tetracycline-induced tooth changes. 2. Prevalence, localization and nature of staining in extracted deciduous teeth. Med J Aust 2: 714–719.
-
127.
Forti G, Benincori C, 1969. Doxycycline and the teeth. Lancet 1: 782.
-
128.
Yagupsky P, 1991. Tetracycline for Rocky Mountain spotted fever. Pediatrics 87: 124–125.
-
129.
Lochary ME, Lockhart PB, Williams WT, 1998. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J 17: 429–431.
-
130.
Thorner AR, Walker DH, Petri WA, 1998. Rocky Mountain spotted fever. Clin Infect Dis 27: 1353–1360.
-
131.
Dalton MJ, Clarke MJ, Holman RC, Krebs JW, Fishbein DB, Olson JG, Childs JE, 1995. National surveillance for Rocky Mountain spotted fever, 1981–1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 52: 405–413.
-
132.
Purvis JJ, Edwards MS, 2000. Doxycycline use for rickettsial disease in pediatric patients. Pediatr Infect Dis J 19: 871–874.
-
133.
Abramson JS, Givner LB, 1990. Should tetracycline be contraindicated for therapy of presumed Rocky Mountain spotted fever in children less than 9 years of age? Pediatrics 86: 123–124.
-
134.
American Academy of Pediatrics, 2006. Redbook: 2006 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics.
-
135.
2001. Update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 50: 1014–1016.
-
136.
Bevelander G, 1964. The effect of tetracycline on mineralization and growth. Adv Oral Biol 1: 205–223.
-
137.
Cohlan SQ, Tiamsic T, Bevelander G, 1963. Growth inhibition of prematures receiving tetracycline. Am J Dis Child 105: 340–347.
-
138.
Nahum GG, Uhl K, Kennedy DL, 2006. Antibiotic use in pregnancy and lactation. Obstet Gynecol 107: 1120–1138.
-
139.
Czeizel AE, Rockenbauer M, 1997. Teratogenic study of doxycycline. Obstet Gynecol 89: 524–528.
-
140.
Briggs G, 2002. Drug effects on the fetus and breast-fed infant. Clin Obstet Gynecol 45: 6–21.
-
141.
Hellgren U, Rombo L, 2010. Alternatives for malaria prophylaxis during the first trimester of pregnancy: our personal view. J Travel Med 17: 130–132.
-
142.
Kutscher AH, Zegarelli EV, Tovell HM, Hochberg B, 1963. Discoloration of teeth induced by tetracycline administered ante partum. JAMA 184: 586–587.
-
143.
Genot MT, Golan HP, Porter PJ, Kass EH, 1970. Effect of administration of tetracycline in pregnancy on the primary dentition of the offspring. J Oral Med 25: 75–79.
-
144.
Kunelis CT, Peters JL, Edmondson HA, 1965. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med 38: 359–377.
-
145.
Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF, 1981. Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 26: 135–141.
-
146.
Schultz JC, Adamson JS Jr, Workman WW, Norman TD, 1963. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 269: 999–1004.
-
147.
Centers for Disease Control and Prevention, 2008. CDC Health Information for International Travel 2008. Atlanta, GA: Elsevier.
-
148.
Morganti G, Ceccarelli G, Ciaffi G, 1968. Comparative concentrations of a tetracycline antibiotic in serum and maternal milk. Antibiotica 6: 216–223.
-
149.
2001. Transfer of drugs and other chemicals into human milk. Pediatrics 108: 776–789.
-
150.
Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, Golper TA, Singer I, 1980. Drug therapy in renal failure: dosing guidelines for adults. Part I: antimicrobial agents, analgesics. Ann Intern Med 93: 62–89.
-
151.
Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, Tillement JP, 1983. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol 16: 245–252.
-
152.
Smith K, Leyden JJ, 2005. Safety of doxycycline and minocycline: a systematic review. Clin Ther 27: 1329–1342.
-
153.
Bryan JP, 2006. Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis. Am J Trop Med Hyg 75: 416–420.
-
154.
The Uncommon Drugstore. Available at: www.drugstore.com. Accessed May 1, 2009
-
155.
GlaxoSmithKline Inc., 2007. Malarone antimalarial agent. Inc. G, ed. Product Monograph. Research Triangle Park, NC: GlaxoSmithKline
-
156.
Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ, 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 54: 62–66.
-
157.
Yeo AE, Edstein MD, Shanks GD, Rieckmann KH, 1997. Potentiation of the antimalarial activity of atovaquone by doxycycline against Plasmodium falciparum in vitro. Parasitol Res 83: 489–491.
-
158.
Canfield C, Pudney M, Gutteridge W, 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 80: 373–381
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 4559 | 3081 | 591 |
| Full Text Views | 2271 | 47 | 10 |
| PDF Downloads | 935 | 48 | 6 |
Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis
Kathrine R. Tan
Kathrine R. Tan
Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia; Walter Reed Army Institute for Research, Silver Spring, Maryland
Search for other papers by Kathrine R. Tan in
Current site
Google Scholar
PubMed
Search for other papers by Kathrine R. Tan in
Current site
Google Scholar
PubMed
Alan J. Magill
Alan J. Magill
Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia; Walter Reed Army Institute for Research, Silver Spring, Maryland
Search for other papers by Alan J. Magill in
Current site
Google Scholar
PubMed
Search for other papers by Alan J. Magill in
Current site
Google Scholar
PubMed
Monica E. Parise
Monica E. Parise
Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia; Walter Reed Army Institute for Research, Silver Spring, Maryland
Search for other papers by Monica E. Parise in
Current site
Google Scholar
PubMed
Search for other papers by Monica E. Parise in
Current site
Google Scholar
PubMed
Paul M. Arguin
Paul M. Arguin
Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia; Walter Reed Army Institute for Research, Silver Spring, Maryland
Search for other papers by Paul M. Arguin in
Current site
Google Scholar
PubMed
Search for other papers by Paul M. Arguin in
Current site
Google Scholar
PubMed
Doxycycline, a synthetically derived tetracycline, is a partially efficacious causal prophylactic (liver stage of Plasmodium) drug and a slow acting blood schizontocidal agent highly effective for the prevention of malaria. When used in conjunction with a fast acting schizontocidal agent, it is also highly effective for malaria treatment. Doxycycline is especially useful as a prophylaxis in areas with chloroquine and multidrug-resistant Plasmodium falciparum malaria. Although not recommended for pregnant women and children < 8 years of age, severe adverse events are rarely reported for doxycycline. This report examines the evidence behind current recommendations for the use of doxycycline for malaria and summarizes the available literature on its safety and tolerability.
Author Notes
Authors' addresses: Kathrine R. Tan and Paul M. Arguin, Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, E-mails: ktan@cdc.gov and parguin@cdc.gov. Alan J. Magill, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, E-mail: alan.magill@us.army.mil. Monica E. Parise, Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, E-mail: mparise@cdc.gov.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Centers for Disease Control and Prevention, 2009. CDC Health Information for International Travel 2010. Atlanta, GA: Elsevier.
-
2.
Griffith KS, Lewis LS, Mali S, Parise ME, 2007. Treatment of malaria in the United States: a systematic review. JAMA 297: 2264–2277.
-
3.
2008. Tetracyclines. McEvoy G, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc.
-
4.
Rieckmann KH, McNamara JV, Willerson D, Kass L, Frischer J, Carson PE, 1971. Effects of tetracycline against chloroquineresistant and cloroquine-sensitive Plasmodium falcuparum. Am J Trop Med Hyg 20: 811–815.
-
5.
Clyde DF, DuPont HL, Hornick RB, 1971. Antimalarial effects of tetracyclines in man. J Trop Med Hyg 74: 238–242.
-
6.
Colwell EJ, Hickman RL, Intraprasert R, Tirabutana C, 1972. Minocycline and tetracycline treatment of acute falciparum malaria in Thailand. Am J Trop Med Hyg 21: 144–149.
-
7.
Colwell EJ, Hickman RL, Kosakal S, 1972. Tetracycline treatment of chloroquine-resistant falciparum malaria in Thailand. JAMA 220: 684–686.
-
8.
Willerson RK Jr, Carson PE, Frischer H, 1972. Effects of minocycline against chloroquine-resistant falciparum malaria. Am J Trop Med Hyg 21: 857–862.
-
9.
Lacy CF, Armstrong LL, Goldmann MP, Leonard LL, 2006. Lexi Comp's Drug Information Handbook. Hudson, OH: Lexi Comp.
-
10.
Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, Tang DB, Dunne MW, Shanks GD, 1998. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 26: 146–150.
-
11.
Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL, 1995. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 171: 1569–1575.
-
12.
Baudon D, Martet G, Pascal B, Bernard J, Keundjian A, Laroche R, 1999. Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil; a study conducted in 1996 in the French Army. Trans R Soc Trop Med Hyg 93: 302–303.
-
13.
Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ, Handschin J, Tang D, Sandjaja B, Tjitra E, Hadiarso L, Watt G, Wignall FS, 1997. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 126: 963–972.
-
14.
Pang L, Limsomwong N, Singharaj P, 1988. Prophylactic treatment of vivax and falciparum malaria with low-dose doxycycline. J Infect Dis 158: 1124–1127.
-
15.
Pang LW, Limsomwong N, Boudreau EF, Singharaj P, 1987. Doxycycline prophylaxis for falciparum malaria. Lancet 1: 1161–1164.
-
16.
Rieckmann KH, Yeo AE, Davis DR, Hutton DC, Wheatley PF, Simpson R, 1993. Recent military experience with malaria chemoprophylaxis. Med J Aust 158: 446–449
-
17.
Watanasook C, Singharaj P, Suriyamongkol V, Karwacki JJ, Shanks D, Phintuyothin P, Pilungkasa S, Wasuwat P, 1989. Malaria prophylaxis with doxycycline in soldiers deployed to the Thai-Kampuchean border. Southeast Asian J Trop Med Public Health 20: 61–64.
-
18.
Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J, 1999. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 28: 74–81.
-
19.
Sanchez JL, DeFraites RF, Sharp TW, Hanson RK, 1993. Mefloquine or doxycycline prophylaxis in US troops in Somalia. Lancet 341: 1021–1022.
-
20.
Shamiss A, Atar E, Zohar L, Cain Y, 1996. Mefloquine versus doxycycline for malaria prophylaxis in intermittent exposure of Israeli Air Force aircrew in Rwanda. Aviat Space Environ Med 67: 872–873.
-
21.
Shanks GD, Roessler P, Edstein MD, Rieckmann KH, 1995. Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia. Mil Med 160: 443–445.
-
22.
Shanks GD, Barnett A, Edstein MD, Rieckmann KH, 1995. Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. Med J Aust 162: 306–307, 309–310.
-
23.
Shmuklarsky MJ, Boudreau EF, Pang LW, Smith JI, Schneider I, Fleckenstein L, Abdelrahim MM, Canfield CJ, Schuster B, 1994. Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. Ann Intern Med 120: 294–299.
-
24.
Willerson D, Rieckmann KH, Carson PE, Frischer H, 1972. Effects of minocycline against chloroquine-resistant falciparum malaria. Am J Trop Med Hyg 21: 857–862.
-
25.
Clyde DF, 1974. Treatment of drug-resistant malaria in man. Bull World Health Organ 50: 243–249.
-
26.
Taylor WR, Widjaja H, Richie TL, Basri H, Ohrt C, Tjitra Taufik E, Jones TR, Kain KC, Hoffman SL, 2001. Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia. Am J Trop Med Hyg 64: 223–228.
-
27.
Ponnampalam JT, 1981. Doxycycline in the treatment of falciparum malaria among aborigine children in West Malaysia. Trans R Soc Trop Med Hyg 75: 372–377.
-
28.
Alecrim MG, Lacerda MV, Mourao MP, Alecrim WD, Padilha A, Cardoso BS, Boulos M, 2006. Successful treatment of Plasmodium falciparum malaria with a six-doxe regimen of artemether-lumefantrine versus quinine-doxycycline in the Western Amazon regioni of Brazil. Am J Trop Med Hyg 74: 20–25.
-
29.
Ejaz A, Haqnawaz Z, Hussain Z, Butt R, Awan ZI, Bux H, 2007. Treatment of uncomplicated Plasmodium falciparum malaria with quinine-doxycycline combination therapy. J Pak Med Assoc 57: 502–505.
-
30.
White NJ, 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41: 1413–1422.
-
31.
Handfield-Jones RP, 1949. Chloroquine, proguanil, mepacrine and quinine in the treatment of malaria caused by Plasmodium falciparum. Ann Trop Med Parasitol 43: 345–348.
-
32.
Watt G, Loesuttivibool L, Shanks GD, Boundreau EF, Brown AE, Pavanand K, Webster HK, Wechgritaya S, 1992. Quinine with tetracycline for the treatment of drug-resistant falciparum malaria in Thailand. Am J Trop Med Hyg 47: 108–111.
-
33.
Reacher M, Campbell CC, Freeman J, Doberstyn EB, Brandling-Bennett AD, 1981. Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine-sulfadoxine (Fansidar). A study of alternate regimens in Eastern Thailand, 1980. Lancet 2: 1066–1069.
-
34.
Looareesuwan S, Vanijanonta S, Viravan C, Wilairatana P, Charoenlarp P, Lasserre R, Canfield C, Kyle DE, Webster HK, 1994. Randomized trial of mefloquine-tetracycline and quinine-tetracycline for acute uncomplicated falciparum malaria. Acta Trop 57: 47–53.
-
35.
Karbwang J, Molunto P, Bunnag D, Harinasuta T, 1991. Plasma quinine levels in patients with falciparum malaria when given alone or in combination with tetracycline with or without primaquine. Southeast Asian J Trop Med Public Health 22: 72–76.
-
36.
2008. Vibramycin. Physicians' Desk Reference. Montvale, NJ: Thomson PDR.
-
37.
Maibach H, 1991. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis 48: 411–417.
-
38.
Leyden JJ, 1985. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. J Am Acad Dermatol 12: 308–312.
-
39.
Meyer FP, Specht H, Quednow B, Walther H, 1989. Influence of milk on the bioavailability of doxycycline–new aspects. Infection 17: 245–246.
-
40.
2002. Product Information: vibramycin brand of doxycycline monohydrate. New York: Pfizer.
-
41.
2003. Tetracyclines (Systemic). Group UDE, ed. USP DI Drug Information for the Health Care Provider. Greenwood Village, CO: Micromedex, Inc.
-
42.
Cunha BA, Comer JB, Jonas M, 1982. The tetracyclines. Med Clin North Am 66: 293–302.
-
43.
Whelton A, Schach von Wittenau M, Twomey TM, Walker WG, Bianchine JR, 1974. Doxycycline pharmacokinetics in the absence of renal function. Kidney Int 5: 365–371.
-
44.
Binh V, Chinh N, Thanh N, Cuong B, Quang N, Dai B, Travers T, Edstein M, 2009. Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. Am J Trop Med Hyg 81: 747–753.
-
45.
Marussig M, Motard A, Renia L, Baccam D, Lebras J, Charmot G, Mazier D, 1993. Activity of doxycycline against preerythrocytic malaria. J Infect Dis 168: 1603–1604.
-
46.
Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ, 2006. Tetracyclines specifically target the apicoplast of the malaria parasite P. falciparum. Antimicrob Agents Chemother 50: 3124–3131.
-
47.
Budimulja AS, Syafruddin Tapchaisri P, Wilairat P, Marzuki S, 1997. The sensitivity of Plasmodium protein synthesis to prokaryotic ribosomal inhibitors. Mol Biochem Parasitol 84: 137–141.
-
48.
Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ, 2006. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 75: 402–415.
-
49.
Pukrittayakamee S, Imwong M, Singhasivanon P, Stepniewska K, Day N, White N, 2008. Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria. Am J Trop Med Hyg 79: 378–384.
-
50.
Wein S, Maynadier M, Tran Van Ba C, Cerdan R, Peyrottes S, Fraisse L, Vial H, 2010. Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J Clin Microbiol 48: 1651–1660.
-
51.
Dahl E, Rosenthal P, 2007. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother 51: 3485–3490.
-
52.
Pradines B, Spiegel A, Rogier C, Tall A, Mosnier J, Fusai T, Trape JF, Parzy D, 2000. Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity of doxycycline against Senegalese isolates. Am J Trop Med Hyg 62: 82–85.
-
53.
Legrand E, Volney B, Meynard JB, Mercereau-Puijalon O, Esterre P, 2008. In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob Agents Chemother 52: 288–298.
-
54.
Briolant S, Baragatti M, Parola P, Simon F, Tall A, Sokhna C, Hovette P, Mamfoumbi M, Koeck J-L, Delmont J, Spiegel A, Castello J, Gardair J, Trape J, Kombila M, Minodier P, Fusai T, Rogier C, Pradines B, 2009. Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline. Antimicrob Agents Chemother 53: 688–695.
-
55.
Briolant S, Wurtz N, Zettor A, Rogier C, Pradines B, 2010. Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers. J Infect Dis 201: 153–159.
-
56.
Shanks GD, Edstein MD, Suriyamongkol V, Timsaad S, Webster HK, 1992. Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. Am J Trop Med Hyg 46: 643–648.
-
57.
Wallace MR, Sharp TW, Smoak B, Iriye C, Rozmajzl P, Thornton SA, Batchelor R, Magill AJ, Lobel HO, Longer CF, Burans JP, 1996. Malaria among United States troops in Somalia. Am J Med 100: 49–55.
-
58.
Pages F, Boutin JP, Meynard JB, Keundijian A, Ryfer S, Giurato L, Baudon D, 2002. Tolerability of doxycycline monohydrate salt vs. chloroquine-proquanil in malaria chemoprophylaxis. Trop Med Int Health 7: 919–924.
-
59.
Durrheim DN, Gammon S, Waner S, Braack LE, 1999. Antimalarial prophylaxis–use and adverse events in visitors to the Kruger National Park. S Afr Med J 89: 170–175.
-
60.
Waner S, Durrhiem D, Braack LE, Gammon S, 1999. Malaria protection measures used by in-flight travelers to South African game parks. J Travel Med 6: 254–257.
-
61.
Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R, 2007. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicenter, randomized, double blind, four arm study. BMJ 327: 1078–1083.
-
62.
Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE, 1990. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg 43: 608–613.
-
63.
Conrad KA, Kiser WR, 1997. Doxycycline vs. mefloquine. Mil Med 162: viii.
-
64.
Korhonen C, Peterson K, Bruder C, Jung P, 2007. Self-reported adverse events associated with antimalarial chemoprophylaxis in Peace Corps volunteers. Am J Prev Med 33: 194–199.
-
65.
Delpre G, Kadish U, Stahl B, 1989. Induction of esophageal injuries by doxycycline and other pills. A frequent but preventable occurrence. Dig Dis Sci 34: 797–800.
-
66.
Jaspersen D, 2000. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf 22: 237–249.
-
67.
Delpre G, Kadish U, 1981. More on esophageal ulcerations due to tetracycline and doxycycline therapy. Gastrointest Endosc 27: 108–109.
-
68.
Berger RS, 1988. A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R. J Clin Pharmacol 28: 367–370.
-
69.
Layton AM, Cunliffe WJ, 1993. Phototoxic eruptions due to doxycycline–a dose-related phenomenon. Clin Exp Dermatol 18: 425–427.
-
70.
Smith EL, al Raddadi A, al Ghamdi F, Kutbi S, 1995. Tetracycline phototoxicity. Br J Dermatol 132: 316–317.
-
71.
Bjellerup M, Ljunggren B, 1994. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema. Br J Dermatol 130: 356–360.
-
72.
Shea CR, Olack GA, Morrison H, Chen N, Hasan T, 1993. Phototoxicity of lumidoxycycline. J Invest Dermatol 101: 329–333.
-
73.
Vassileva SG, Mateev G, Parish LC, 1998. Antimicrobial photosensitive reactions. Arch Intern Med 158: 1993–2000.
-
74.
Gonzalez E, Gonzalez S, 1996. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 35: 871–885, quiz 886–887.
-
75.
Sobel JD, 1985. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 152: 924–935.
-
76.
McCool L, Mai H, Essmann M, Larsen B, 2008. Tetracycline effects on Candida albicans virulence factors. Infect Dis Obstet Gynecol 2008: 493508.
-
77.
Caruso LJ, 1964. Vaginal moniliasis after tetracycline therapy: the effects of amphotericin B. Am J Obstet Gynecol 90: 374–378.
-
78.
Oriel JD, Waterworth PM, 1975. Effects of minocycline and tetracycline on the vaginal yeast flora. J Clin Pathol 28: 403–406.
-
79.
Hall JH, Lupton ES, 1977. Tetracycline therapy for acne: incidence of vaginitis. Cutis 20: 97–98.
-
80.
Friedman DI, 2005. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol 6: 29–37.
-
81.
Walters BN, Gubbay SS, 1981. Tetracycline and benign intracranial hypertension: report of five cases. Br Med J (Clin Res Ed) 282: 19–20.
-
82.
Winn BJ, Liao YJ, Horton JC, 2007. Intracranial pressure returns to normal about a month after stopping tetracycline antibiotics. Arch Ophthalmol 125: 1137–1138.
-
83.
Meynadier J, Alirezai M, 1998. Systemic antibiotics for acne. Dermatology 196: 135–139.
-
84.
Morrow GL, Abbott RL, 1998. Minocycline-induced scleral, dental, and dermal pigmentation. Am J Ophthalmol 67: 450–455.
-
85.
Loo WJ, Kirtschig G, Wojnarowska F, 2001. Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol 26: 376–379.
-
86.
Ozog DM, Gogstetter DS, Scott G, Gaspari AA, 2000. Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid. Arch Dermatol 136: 1136–1138.
-
87.
Patel K, Cheshire D, Vance A, 1998. Oral and systemic effects of prolonged minocycline therapy. Br Dent J 185: 560–562.
-
88.
Wasel NR, Schloss EH, Lin AN, 1998. Minocycline-induced cutaneous pigmentation. J Cutan Med Surg 3: 105–108.
-
89.
Westermann GW, Bohm M, Bonsmann G, Rahn KH, Kisters K, 1999. Chronic intoxication by doxycycline use for more than 12 years. J Intern Med 246: 591–592.
-
90.
Chiappinelli JA, Walton RE, 1992. Tooth discoloration resulting from long-term tetracycline therapy: a case report. Quintessence Int 23: 539–541.
-
91.
Ho NC, Levy H, Francomano CA, Elkayam O, 2000. Minocycline-induced generalized postinflammatory elastolysis. Am J Med 109: 340–341.
-
92.
Dotevall L, Hagberg L, 2000. Adverse effects of minocycline versus doxycycline in the treatment of Lyme neuroborreliosis. Clin Infect Dis 30: 410–411.
-
93.
Golledge CL, Riley TV, 1995. Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis. Lancet 345: 1377–1378.
-
94.
Baxter R, Ray GT, Fireman B, 2008. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 29: 44–50.
-
95.
2007. Vibramycin [package insert]. New York: Pfizer Labs.
-
96.
Delaney TJ, Leppard BJ, MacDonald DM, 1974. Effects of leng-term treatment with tetracycline. Acta Dematovener (Stockholm) 54: 487–489.
-
97.
Tanzman ES, 1988. Long-term tetracycline use in the treatment of acne vulgaris–the role of routine laboratory monitoring. J Am Coll Health 36: 272–278.
-
98.
Sauer GC, 1976. Safety of long-term tetracycline therapy for acne. Arch Dermatol 112: 1603–1605.
-
99.
Abe M, Furukawa S, Takayama S, Michitaka K, Minami H, Yamamoto K, Horiike N, Onji M, 2003. Drug-induced hepatitis with autoimmune features during minocycline therapy. Intern Med 42: 48–52.
-
100.
Goldstein NS, Bayati N, Silverman AL, Gordon SC, 2000. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 114: 591–598.
-
101.
Gough A, Chapman S, Wagstaff K, Emery P, Elias E, 1996. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 312: 169–172.
-
102.
Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM, 1998. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med 152: 1132–1136.
-
103.
Malcolm A, Heap TR, Eckstein RP, Lunzer MR, 1996. Minocycline-induced liver injury. Am J Gastroenterol 91: 1641–1643.
-
104.
Heaton PC, Fenwick SR, Brewer DE, 2007. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther 32: 483–487.
-
105.
Goulden V, Glass D, Cunliffe WJ, 1996. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 134: 693–695.
-
106.
O'dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, Sems KM, Fernandez AM, Palmer WR, Klassen LW, Paulsen GA, Haire CE, Moore GF, 2001. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 44: 2235–2241.
-
107.
Zhang L, Zhang Y, Zhao P, Huang S, 2009. Predicting drug-drug interactions: and FDA perspective. AAPS J 11: 300–306.
-
108.
Deppermann K, Lode H, Joffken G, Tschink G, Kalz C, Koeppe P, 1989. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycyline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 33: 1901–1907.
-
109.
Helms SE, Bredle DL, Zajic J, Jarjoura D, Brodell RT, Krishnarao I, 1997. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 36: 705–710.
-
110.
Dickinson BD, Altman RD, Nielson NH, Sterling ML, 2001. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 98: 853–860.
-
111.
Neely JL, Abate M, Swinker M, D'Angio R, 1991. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstet Gynecol 77: 416–420.
-
112.
Archer JS, Archer DF, 2002. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 46: 917–923.
-
113.
Baciewicz AM, Bal BS, 2001. Bleeding associated with doxycycline and warfarin treatment. Arch Intern Med 161: 1231.
-
114.
Jawetz E, Gunnison JB, 1952. Studies on antibiotic synergism and antagonism: a scheme of combined antibiotic action. Antibiot Chemother 2: 243–248.
-
115.
Kuzucu EY, 1970. Methoxyflurane, tetracycline, and renal failure. JAMA 211: 1162–1164.
-
116.
Cousins MJ, Mazze RI, 1972. Tetracycline, methoxyflurane anaesthesia, and renal dysfunction. Lancet 1: 751–752.
-
117.
Frascino JA, 1972. Tetracycline, methoxyflurane anaesthesia, and renal dysfunction. Lancet 1: 1127.
-
118.
Lindenbaum J, Rund DG, Butler VP, Tse-eng D, Saha JR, 1981. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 305: 789–794.
-
119.
Lindenbaum J, Tse-eng D, Butler VP, Rund DG, 1981. Urinary excretion of reduced metabolites of digoxin. Am J Med 71: 71–74.
-
120.
Neuvonen PJ, Penttila O, Lehtovaara R, Aho K, 1975. Effect of antiepileptic drugs on the elimination of various tetracycline derivatives. Eur J Clin Pharmacol 9: 147–154.
-
121.
2006. Vivotif [package insert]. Switzerland: Berna Biotech Ltd.
-
122.
Conchie JM, Munroe JD, Anderson DO, 1970. The incidence of staining of permanent teeth by the tetracyclines. CMAJ 103: 351–356.
-
123.
Wallman IS, Hilton HB, 1962. Teeth pigmented by tetracycline. Lancet 1: 827–829.
-
124.
Briggs GG, Freeman RK, Yaffe SJ, 2005. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Philadelphia, PA: Lippincott, Williams, & Wilkins.
-
125.
Grossman ER, Walchek A, Freedman H, 1971. Tetracyclines and permanent teeth: the relation between dose and tooth color. Pediatrics 47: 567–570.
-
126.
Brearley LJ, Storey E, 1968. Tetracycline-induced tooth changes. 2. Prevalence, localization and nature of staining in extracted deciduous teeth. Med J Aust 2: 714–719.
-
127.
Forti G, Benincori C, 1969. Doxycycline and the teeth. Lancet 1: 782.
-
128.
Yagupsky P, 1991. Tetracycline for Rocky Mountain spotted fever. Pediatrics 87: 124–125.
-
129.
Lochary ME, Lockhart PB, Williams WT, 1998. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J 17: 429–431.
-
130.
Thorner AR, Walker DH, Petri WA, 1998. Rocky Mountain spotted fever. Clin Infect Dis 27: 1353–1360.
-
131.
Dalton MJ, Clarke MJ, Holman RC, Krebs JW, Fishbein DB, Olson JG, Childs JE, 1995. National surveillance for Rocky Mountain spotted fever, 1981–1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 52: 405–413.
-
132.
Purvis JJ, Edwards MS, 2000. Doxycycline use for rickettsial disease in pediatric patients. Pediatr Infect Dis J 19: 871–874.
-
133.
Abramson JS, Givner LB, 1990. Should tetracycline be contraindicated for therapy of presumed Rocky Mountain spotted fever in children less than 9 years of age? Pediatrics 86: 123–124.
-
134.
American Academy of Pediatrics, 2006. Redbook: 2006 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics.
-
135.
2001. Update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 50: 1014–1016.
-
136.
Bevelander G, 1964. The effect of tetracycline on mineralization and growth. Adv Oral Biol 1: 205–223.
-
137.
Cohlan SQ, Tiamsic T, Bevelander G, 1963. Growth inhibition of prematures receiving tetracycline. Am J Dis Child 105: 340–347.
-
138.
Nahum GG, Uhl K, Kennedy DL, 2006. Antibiotic use in pregnancy and lactation. Obstet Gynecol 107: 1120–1138.
-
139.
Czeizel AE, Rockenbauer M, 1997. Teratogenic study of doxycycline. Obstet Gynecol 89: 524–528.
-
140.
Briggs G, 2002. Drug effects on the fetus and breast-fed infant. Clin Obstet Gynecol 45: 6–21.
-
141.
Hellgren U, Rombo L, 2010. Alternatives for malaria prophylaxis during the first trimester of pregnancy: our personal view. J Travel Med 17: 130–132.
-
142.
Kutscher AH, Zegarelli EV, Tovell HM, Hochberg B, 1963. Discoloration of teeth induced by tetracycline administered ante partum. JAMA 184: 586–587.
-
143.
Genot MT, Golan HP, Porter PJ, Kass EH, 1970. Effect of administration of tetracycline in pregnancy on the primary dentition of the offspring. J Oral Med 25: 75–79.
-
144.
Kunelis CT, Peters JL, Edmondson HA, 1965. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med 38: 359–377.
-
145.
Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF, 1981. Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 26: 135–141.
-
146.
Schultz JC, Adamson JS Jr, Workman WW, Norman TD, 1963. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 269: 999–1004.
-
147.
Centers for Disease Control and Prevention, 2008. CDC Health Information for International Travel 2008. Atlanta, GA: Elsevier.
-
148.
Morganti G, Ceccarelli G, Ciaffi G, 1968. Comparative concentrations of a tetracycline antibiotic in serum and maternal milk. Antibiotica 6: 216–223.
-
149.
2001. Transfer of drugs and other chemicals into human milk. Pediatrics 108: 776–789.
-
150.
Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, Golper TA, Singer I, 1980. Drug therapy in renal failure: dosing guidelines for adults. Part I: antimicrobial agents, analgesics. Ann Intern Med 93: 62–89.
-
151.
Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, Tillement JP, 1983. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol 16: 245–252.
-
152.
Smith K, Leyden JJ, 2005. Safety of doxycycline and minocycline: a systematic review. Clin Ther 27: 1329–1342.
-
153.
Bryan JP, 2006. Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis. Am J Trop Med Hyg 75: 416–420.
-
154.
The Uncommon Drugstore. Available at: www.drugstore.com. Accessed May 1, 2009
-
155.
GlaxoSmithKline Inc., 2007. Malarone antimalarial agent. Inc. G, ed. Product Monograph. Research Triangle Park, NC: GlaxoSmithKline
-
156.
Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ, 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 54: 62–66.
-
157.
Yeo AE, Edstein MD, Shanks GD, Rieckmann KH, 1997. Potentiation of the antimalarial activity of atovaquone by doxycycline against Plasmodium falciparum in vitro. Parasitol Res 83: 489–491.
-
158.
Canfield C, Pudney M, Gutteridge W, 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 80: 373–381
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 4559 | 3081 | 591 |
| Full Text Views | 2271 | 47 | 10 |
| PDF Downloads | 935 | 48 | 6 |